Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arena Pharmaceuticals, Inc. - Common Stock (NQ: ARNA )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Mar 10, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arena Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 Next >
NeurAxis: Should You Buy This IPO?
As NeurAxis is ready to launch its IPO, we take a closer look to see if investors should be buying into the hype. 
Via Talk Markets
NeurAxis IPO Sets Stage To Take On Irritable Bowel Syndrome With A Non-Surgical Solution
As NeurAxis gears up for its upcoming IPO, we take a deep dive into the company to see if it's worth adding to your investment portfolio. 
Via Talk Markets
Arena Pharmaceuticals Inc. Climbs To Annual-High Share Price
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Arena Pharmaceuticals Inc. (NASDAQ: ARNA... 
Via Benzinga
Arena Pharmaceuticals Inc. (ARNA) Climbs to Annual-High Share Price
Via Investor Brand Network
Arena Pharmaceuticals Inc. (ARNA) Climbs to Annual-High Share Price
Via Investor Brand Network
7 Biotech Stocks With Key Catalysts in March
These seven stocks have some key catalysts lined up for March with the potential to move their price actions in big ways. 
Via InvestorPlace
Expert Ratings For Arena Pharmaceuticals
Arena Pharmaceuticals (NASDAQ:ARNA) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Bullish Tuesday For Marijuana Stocks - Nine Energy Service, ReneSola Among Top Gainers
GAINERS: Nine Energy Service (NYSE: 
Via Benzinga
Futures Rebound On "Massive" EU Bond Stimulus Plan; Nickel Halted After Record Surge, Gold Over $2000
Futures rebounded from yesterday huge loss, and after touching a session low of 4,138, S&P futures bounced shortly after the European when Bloomberg reported that the European Union was set to reveal a... 
Via Talk Markets
Pfizer's Cannabinoid-Related Biotech Company Arena's Q4 Net Loss Grows 27% YoY
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) revealed Wednesd... 
Via Benzinga
Arena Pharmaceuticals: Q4 Earnings Insights
Arena Pharmaceuticals (NASDAQ:ARNA) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:00 PM. Here's what investors need to know about the announcement.... 
Via Benzinga
Arena Reports Fourth Quarter and Full Year 2021 Financial Results and Key Program Updates
From Arena Pharmaceuticals, Inc.
Via Business Wire
The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase... 
Via Benzinga
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Arena Pharmaceuticals, Inc.
Via Business Wire
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
Via Benzinga
Arena Pharmaceuticals to Release Fourth Quarter and Full-Year 2021 Financial Results and Provide Corporate Update on February 23
From Arena Pharmaceuticals, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For February 9, 2022
Upgrades According to Capital One, the prior rating for Federal Realty Investment Trust (NYSE:FRT) was changed from Equal-Weight to Overweight. Federal Realty Investment... 
Via Benzinga
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Arena Pharmaceuticals, Inc.
Via Business Wire
7 Long-Term Stocks to Buy and Hold Until 2030
Long-term stocks that promise to be value creators with a robust business model and positive industry tailwinds. Companies that are positioned for robust free cash flows. 
Via InvestorPlace
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Arena Pharmaceuticals, Inc.
Via Business Wire
10 Biggest Price Target Changes For Tuesday
B of A Securities lifted the price target on Micron Technology, Inc. (NASDAQ: 
Via Benzinga
Benzinga's Bulls And Bears Of The Past Week: Pfizer, Bank Of America, Beyond Meat, GameStop, AMC, Overstock And More
Benzinga has examined the prospects for many investor favorite stocks over the... 
Via Benzinga
The Week In Cannabis: Pfizer, Visa, $730M+ In Financings, Malta, EU, Columbia Care, MedMen, Uruguay And More
Below is a recap of the main news related to the cannabis industry and markets for the week of December 13, 2021. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2021
Upgrades According to Wells Fargo, the prior rating for Douglas Emmett Inc (NYSE: 
Via Benzinga
What 6 Analyst Ratings Have To Say About Arena Pharmaceuticals
Over the past 3 months, 6 analysts have published their opinion on Arena Pharmaceuticals (NASDAQ: 
Via Benzinga
10 Biggest Price Target Changes For Tuesday
B of A Securities lifted the price target on Apple Inc. (NASDAQ: AAPL) from $160 to $210. Apple shares rose 0.4% to $176.37 in pre-market trading. JP Morgan lowered Zscaler,... 
Via Benzinga
58 Biggest Movers From Yesterday
Gainers Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) shares jumped 80.4% to close at $90.08 on Monday. Pfizer agreed to acquire Arena Pharmaceuticals for $100 per share in an all-... 
Via Benzinga
Vaccine Stocks Get A Booster As U.K. Plans Third Jab For All
Covid vaccine stocks jumped Monday on worries that the omicron variant of the virus could soon overwhelm the United Kingdom. 
Via Investor's Business Daily
Mid-Afternoon Market Update: Dow Tumbles Over 200 Points; BELLUS Health Shares Spike Higher
Toward the end of trading Monday, the Dow traded down 0.67% to 35,728.62 while the NASDAQ fell 0.92% to 15,487.41. The S&P also fell, dropping 0.58% to 4,684.47. The U.S. has... 
Via Benzinga
Mid-Day Market Update: Nasdaq Drops Over 100 Points; Foghorn Therapeutics Shares Surge
Midway through trading Monday, the Dow traded down 0.81% to 35,679.10 while the NASDAQ fell 0.78% to 15,509.01. The S&P also fell, dropping 0.67% to 4,680.56. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.